Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irwin Lucki

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Current Pharmaceutical Design|January 11, 2005
Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral geneticsJames J Crowley, Irwin Lucki
European Journal of Pharmacology|January 29, 2020
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depressionCaroline A Browne, Tiffany Smith, Irwin Lucki
Frontiers in Synaptic Neuroscience|December 25, 2018
Dysregulation of the Lateral Habenula in Major Depressive DisorderCaroline A Browne, Robert Hammack, Irwin Lucki
Psychopharmacology|November 12, 2002
Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant actionMichelle E Page, Kevin Brown, Irwin Lucki
Progress in Neurobiology|May 12, 2009
5-HT(1A) receptor function in major depressive disorderJonathan Savitz, Irwin Lucki, Wayne C Drevets
Trends in Pharmacological Sciences|May 15, 2002
Assessing antidepressant activity in rodents: recent developments and future needsJohn F Cryan, Athina Markou, Irwin Lucki
Handbook of Experimental Pharmacology|February 13, 2021
Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive DisorderCaroline A Browne, Hildegard Wulf, Irwin Lucki
Neuroscience and Biobehavioral Reviews|May 18, 2013
Effects of diabetes on hippocampal neurogenesis: links to cognition and depressionNancy Ho, Marilyn S Sommers, Irwin Lucki
Frontiers in Pain Research (Lausanne, Switzerland)|February 16, 2026
The nonhallucinogenic ketamine metabolite (2R,6R)-hydroxynorketamine is a novel analgesic in animal models of painBruno Carabelli, Caroline A Browne, Irwin Lucki
Physiology & Behavior|January 17, 2017
Hair corticosterone measurement in mouse models of type 1 and type 2 diabetes mellitusRebecca L Erickson, Caroline A Browne, Irwin Lucki
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Current Pharmaceutical Design|January 11, 2005
Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral geneticsJames J Crowley, Irwin Lucki
European Journal of Pharmacology|January 29, 2020
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depressionCaroline A Browne, Tiffany Smith, Irwin Lucki
Frontiers in Synaptic Neuroscience|December 25, 2018
Dysregulation of the Lateral Habenula in Major Depressive DisorderCaroline A Browne, Robert Hammack, Irwin Lucki
Psychopharmacology|November 12, 2002
Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant actionMichelle E Page, Kevin Brown, Irwin Lucki
Progress in Neurobiology|May 12, 2009
5-HT(1A) receptor function in major depressive disorderJonathan Savitz, Irwin Lucki, Wayne C Drevets
Trends in Pharmacological Sciences|May 15, 2002
Assessing antidepressant activity in rodents: recent developments and future needsJohn F Cryan, Athina Markou, Irwin Lucki
Handbook of Experimental Pharmacology|February 13, 2021
Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive DisorderCaroline A Browne, Hildegard Wulf, Irwin Lucki
Neuroscience and Biobehavioral Reviews|May 18, 2013
Effects of diabetes on hippocampal neurogenesis: links to cognition and depressionNancy Ho, Marilyn S Sommers, Irwin Lucki
Frontiers in Pain Research (Lausanne, Switzerland)|February 16, 2026
The nonhallucinogenic ketamine metabolite (2R,6R)-hydroxynorketamine is a novel analgesic in animal models of painBruno Carabelli, Caroline A Browne, Irwin Lucki
Physiology & Behavior|January 17, 2017
Hair corticosterone measurement in mouse models of type 1 and type 2 diabetes mellitusRebecca L Erickson, Caroline A Browne, Irwin Lucki
Pageof 10